Supplementary Table S3 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
crossref（2024）
摘要
Supplementary Table S3. Anti-tumor activity by lines of previous systemic regimens (intention-to-treat set).
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要